BusinessSummit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical TrialBy Nasdaq OMXNov 20, 2017, 12:00 PM UTC
BusinessActinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology PlatformBy Nasdaq OMXNov 14, 2017, 1:01 PM UTC
BusinessActinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail RobozBy Nasdaq OMXNov 13, 2017, 12:30 PM UTC
BusinessProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic BlindnessBy Nasdaq OMXNov 13, 2017, 12:00 PM UTC
BusinessImmuron Successfully Completes NASH Phase II Clinical Study MilestoneBy Nasdaq OMXNov 9, 2017, 2:01 PM UTC
BusinessHelmsley Charitable Trust Awards $52 Million to Support the Global Platform for the Prevention of Autoimmune DiabetesBy Nasdaq OMXNov 6, 2017, 2:00 PM UTC
BusinessVBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 MillionBy Nasdaq OMXOct 30, 2017, 12:01 PM UTC
BusinessVaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)By Nasdaq OMXOct 26, 2017, 2:23 PM UTC
